Skip to content

Molecular Analysis of Retinoblastoma

Molecular Analysis of Retinoblastoma

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00718783
Enrollment
41
Registered
2008-07-21
Start date
2007-04-30
Completion date
2016-12-31
Last updated
2016-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinoblastoma

Brief summary

Retinoblastoma is a childhood tumor of the retina that affects approximately 1 in 18,000 children. Retinoblastoma is more prevalent in Central America, where most patients present with advanced intraocular and extraocular disease. Therefore, we have formed collaboration with Central American investigators to provide us with frozen retinoblastoma tumors from patients undergoing routine enucleation. The objective of this protocol is to begin to identify the mutations and gene expression changes that occur in retinoblastoma cells following RB1 gene inactivation in order to more effectively target chemotherapy for treating bilateral retinoblastoma.

Detailed description

This is a biology protocol with no treatment regimen associated. Following routine enucleation of the retinoblastoma affected eye, a portion of the tumor will be removed and flash frozen and sent to St. Jude for RNA and DNA analysis. Some tissue will undergo histopathological analysis and tissue microarrays will be isolated.

Interventions

OTHERTissue samples taken from retinoblastoma

Tissue banking

OTHER5 ml peripheral blood

White blood cells will be isolated from the blood sample as a source of genomic DNA.

Sponsors

National Eye Institute (NEI)
CollaboratorNIH
St. Jude Children's Research Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Must have clinical diagnosis of retinoblastoma (to be confirmed histologically after enucleation) * Legal guardians must willing to sign an informed consent indicating that they are aware of this study and its possible benefits. Legal guardians will be given a copy of the consent form. * Patient is being seen at this AHOPCA institution:

Exclusion criteria

* Ophthalmologist or oncologist is concerned that sampling will interfere with staging. * Diagnosis other than retinoblastoma. * Affiliated hospital is unable to provide pathologic evidence of retinoblastoma.

Design outcomes

Primary

MeasureTime frame
Identify genes exhibiting differential expression within intraocular disease tissue between patients having only intraocular involvement and those having extraocular involvement.Indefinite

Countries

Chile, Honduras

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026